"I believe our eventual, greatest successes will come from mutually beneficial associations and partnerships formed with other companies and institutions. In-licensing and out-licensing opportunities can be rewarding to both parties, creating advances in medicine and technology through relationships with outside scientists and business development executives in academia and corporate R & D."

Darrell Brookstein - Executive VP, Business Development & Finance

Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH. Stellar KLH currently sells into growing academic, research, pharmaceutical markets.